©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
A cDNA Encoding the Calcitonin Gene-related Peptide Type 1 Receptor (*)

(Received for publication, February 20, 1996)

Nambi Aiyar (1) Kinneret Rand (3) Nabil A. Elshourbagy (2) Zhizhen Zeng (3) John E. Adamou (2) Derk J. Bergsma (2)(§) Yi Li (3)(¶)

From the  (1)Departments of Cardiovascular Pharmacology and (2)Molecular Genetics, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 and the (3)Department of Molecular Genetics, Human Genome Sciences, Inc., Rockville, Maryland 20850

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse biological effects including potent vasodilator activity. We report here the cloning of a complementary DNA (cDNA) encoding a human CGRP(1) receptor, which shares significant peptide sequence homology with the human calcitonin receptor, a member of the G-protein-coupled receptor superfamily. Northern blot analysis revealed that the messenger RNA for this receptor is predominantly expressed in the lung and heart. In situ studies showed specific localization of the receptor mRNA to alveolar cells in the lung and to cardiac myocytes in the heart. Stable expression of the cDNA in human embryonic kidney 293 (HEK 293) cells produced specific, high affinity binding sites for CGRP that displayed pharmacological and functional properties very similar to native human CGRP(1) receptor. Exposure of these cells to CGRP resulted in a 60-fold increase in cAMP production, which was inhibited in a competitive manner by the CGRP(1) receptor antagonist, CGRP-(8-37).


INTRODUCTION

Calcitonin gene-related peptide (CGRP) (^1)is 37-amino acid peptide that exists as highly homologous alpha or beta isoforms in both human and rat (1, 2) . alpha- and beta-CGRP display very similar biological activities, including peripheral and cerebral vasodilation(3) , cardiac acceleration(4) , regulation of calcium metabolism(5) , reduction of intestinal motility(6) , regulation of glucose metabolism (reduction of insulin secretion and insulin sensitivity)(7) , diminution of appetite (8) , and reduction of growth hormone release(9) . The two CGRP peptides differ by 3 amino acids in humans and 1 amino acid in rats. The amino acid sequences of CGRP peptides are well conserved among species and can be considered as members of a family of peptides including the related peptides amylin (46% homology), salmon calcitonin (32% homology), and adrenomedullin (24% homology). These peptides in general have N-terminal ring structures of 6-7 amino acids involving a disulfide bridge and an amidated C-terminal end(10, 11, 12) .

CGRP peptides are localized predominantly in sensory afferent nerves and central neurons(11, 12) . When released from the cell, the peptides initiate their biological responses by binding to specific cell surface receptors which are predominantly coupled to the activation of adenylyl cyclase(3, 13) . CGRP receptors have been identified and pharmacologically evaluated in several tissues, including brain, cardiovascular, endothelial, and smooth muscle tissues(12) . Multiple CGRP receptors have been observed: based on pharmacological properties they are divided into at least two subtypes and denoted as CGRP(1) and CGRP(2), according to the classification of Dennis et al.(14) . CGRP-(8-37), which lacks 7 N-terminal amino acid residues, is a selective antagonist of CGRP(1) receptors, whereas the linear analog of CGRP, diacetoamidomethyl cysteine CGRP (Cys(ACM2,7)CGRP), is a selective agonist of CGRP(2) receptors(14) .

A deeper understanding of the physiological and pathophysiological effects mediated by the CGRP peptides has been constrained for lack of a cloned cognate receptor. Here we describe the isolation by expressed sequence tag (EST) analysis (15, 16, 17) of a human CGRP receptor that exhibits ligand binding and functional properties of the CGRP(1) receptor. Curiously, this receptor had been cloned previously as an orphan calcitonin-like receptor receptor (rat (18) and, recently, human(19) ), but the authors had been unable to demonstrate an interaction with CGRP or any other ligands.


EXPERIMENTAL PROCEDURES

Materials

[2-[I]iodohistidyl]Human (h) CGRPalpha (specific activity 2000 Ci/mmol) was obtained from Amersham. hCGRPalpha, hCGRPalpha-(8-37), salmon calcitonin (CT), human CT, porcine vasoactive intestinal peptide, and angiotensin II were purchased from Bachem Biochemicals. Cys(ACM2,7)CGRP was obtained from Phoenix Pharmaceuticals (Belmont, CA). Salmon CT-(8-32) was synthesized at SmithKline Beecham Pharmaceuticals. BCA protein assay kit was obtained from Pierce. All other reagents were obtained from Sigma.

cDNA Cloning

Expressed sequence tag (EST) analysis (15, 16, 17) of cDNA clones derived from a human synovial tissue cDNA library (oligo(dT)-primed and constructed in the ZAPII vector (Stratagene)) identified a 800-bp clone demonstrating significant homology to the human CT receptor. This cDNA clone encoding an incomplete hCGRP(1) receptor was used as a probe to screen an oligo(dT)-primed human lung cDNA library constructed in the ZAPII vector (Stratagene). cDNA library construction and screening were carried out essentially as described(20) . Several positive clones were obtained, the longest of which was sequenced to completion by a ABI sequencer (15) (GenBank accession number L76380).

Stable Expression in HEK 293 Cells

The CGRP receptor has three potential in-frame ATG start codons; however, the most 3[prime-ATG codon resides in the most favorable Kozak consensus context. For this reason, and to potentially increase protein translation efficiency(21) , we prepared a 1.4-kilobase cDNA fragment by PCR amplification that encompassed the entire CGRP receptor coding region, beginning with the 3`-most ATG codon, and subcloned this fragment into the mammalian expression vector, pCDN(22) . The oligonucleotide primers used for PCR amplification were 5`-G GGG TAC CCC ACC ATG GAG AAA AAG TGT ACC TCG TAT TTT CTG G-3` and 5`-CGG GAT CCC GCA AAC AGT GAG ACA ACC ATC CTT CTA TTT TCA AT-3` (the translation start and stop codons are underlined). Human HEK 293 cells were grown in 100-mm culture dishes and transfected with 10 µg of the CDN-CGRP-receptor cDNA using the LipofectAMINE transfection reagent (Life Technologies, Inc.) according to the manufacturer's instructions. After 2 weeks of G418 selection (0.8 mg/ml), colonies were picked and expanded. A single cell line (among many potential candidates) that functionally responded to CGRP treatment (by the generation of cAMP) was chosen for further analysis. A single cell line transfected with pCDN vector alone was selected for use as a control for functional and binding assays.

Northern Blot Analysis

Total RNA was isolated from human tissues by TriZOL Reagent (Life Technologies, Inc.). 20 µg of total RNA from each tissue was separated by formaldehyde, 1.0% agarose gel electrophoresis and transferred to a nylon membrane. The full-length human CGRP(1) cDNA was labeled and used as probe. Hybridization was done essentially as described(23) .

In Situ Gene Amplification Analysis

Under anesthesia, a BALB/C mouse was perfused with 4% paraformaldehyde/phosphate-buffered saline, pH 7.5. Organs were dissected, fixed in 10% buffered formalin at room temperature for 3 days, then embedded in paraffin. Sections of 5 µm were prepared. Reverse transcriptase in situ gene amplification was performed as described(24) . Two primers used in this study were chosen from regions unique to the human CGRP(1) and very similar to the rat CT-like cDNA sequence (18) receptor, but not significantly conserved in the calcitonin receptor(20) : the upstream primer sequence was 5` GAC ATC CAG CAA GCA ACA GA 3`; the downstream primer sequence was 5` CA ATG CCA AGC AAT GGC ACC 3`. Digoxigenin-dUTP was applied to the reaction of gene amplification. The products derived from gene amplification were detected by anti-digoxigenin antibody conjugated to alkaline phosphatase (Genius3, Boehringer Mannheim).

Binding Assays

Radioligand binding assays were performed as described(25) . In saturation binding studies, increasing concentrations of I-CGRP (8 pM to 150 pM) were added to membranes (25 µg) and incubated in a total volume of 500 µl for 60 min, at 25 °C. In competition binding studies, the membranes (30 µg of membrane proteins) were incubated with increasing concentrations (1 pM to 1 µM) of competing ligands and 60 pMI-CGRP for 60 min at 25 °C. Nonspecific binding was defined in the presence of 1 µM alphaCGRP and was usually 20% for transfected cell membranes and <10% for human neuroblastoma SK-N-MC cell (ATCC HTB-10) membranes. No specific binding was observed in membranes of untransfected control 293 cells.

Functional Assays

Transformed or untransformed 293 cells were plated at 2.5 times 10^3 cells/well in 6-well plates. On day 4, the medium was aspirated and the cells were washed with 1 ml of Dulbecco's phosphate-buffered saline containing 0.5 mM isobutylmethylxanthine for 10 min at room temperature. The cells were treated with various concentrations (1 pM to 1 µM) of alphaCGRP or related peptides at 37 °C for 10 min. The reaction was stopped by addition of 100 µl of 100% ice-cold trichloroacetic acid to each well, and cAMP in each well was measured following the radioimmunoassay protocol as described (Advance Magnetics). Each experiment was performed in triplicate and repeated 2-3 times with different passages of cells.


RESULTS AND DISCUSSION

We hypothesized that the CGRP and recently cloned calcitonin (CT) receptors might display close homology since (i) like the G-protein-coupled CT receptor(26) , CGRP signaling appears to be mediated through the activation of adenylyl cyclase, (ii) at high concentrations CT interacts with the CGRP binding site(27) , and (iii) CGRP (the alpha, not beta, isopeptide) and CT share the same mRNA transcript and are produced through alternate splicing(1) , as are the substance P/K ligands that cross-interact with tachykinin receptors (28) . Thus, when expressed sequence tag (EST) analysis (15, 16, 17) of cDNA clones derived from a human synovial tissue cDNA library identified a clone demonstrating significant homology to the human CT receptor, this cDNA was selected for further evaluation. Since the cDNA insert was incomplete (i.e. about 800 bp), it was used as a probe to screen a human lung cDNA library to isolate a clone with a complete open reading frame.

Fig. 1shows the 2995-bp nucleotide sequence and deduced protein of the cloned cDNA. Three potential in-frame ATG codons precede the open reading frame of the protein; however, translation from the second or third ATG codon will encode a protein with a size consistent with that predicted for the cloned rat CT-like ``orphan'' receptor, with which it shares 91% amino acid sequence homology and thus likely represents a receptor ortholog(18) . Also, since the third ATG most closely approximates a Kozak consensus translation initiation site(29) , it is probably the translation initiation codon. Consequently, the cDNA encodes a protein of 461 amino acids, sharing several features in common with the G-protein-linked receptors (30, 31) . Most prominent is the existence of seven hydrophobic regions of 16 to 28 amino acids each, which are likely to be membrane-spanning domains that form a seven-transmembrane motif found among G-protein-coupled receptors. In addition, 52 amino acid residues highly conserved among a recently described subfamily of G-protein-coupled receptors including calcitonin (CT), secretin, parathyroid, glucagon, and other receptors(20, 26, 32, 33, 34) , are also present, interspersed within the sequence. Among this subfamily, the cloned protein shares its greatest sequence identity, 55.5%, with the human CT receptor. Furthermore, within the N-terminal domain there are several sites for post-translational modification including three asparagine residues within consensus sites for glycosylation and a potential cleavage site of an N-terminal hydrophobic sequence that may be a signal peptide.


Figure 1: Nucleotide and deduced amino acid sequence of the human CGRP(1) receptor. Amino acids (represented by the one-letter code) are indicated below their respective codons and numbered 1 at the left beginning with the ATG initiation methionine codon (M). Other numbers on the right indicate nucleotide positions starting at position 1 of the A nucleotide of the ATG codon. Underlined amino acid sequences, putative seven transmembrane domains; potential sites for post-translational glycosylation are marked above the sequence by closed circle; circled amino acids are those that are highly conserved among the secretin/CT/PTH/PTH-RP/GLP1/GHRH/GLU G-protein-coupled receptor subfamily(20, 26, 30, 31, 32) ; arrow, a putative secretory signal sequence cleavage site; double-underlined ATG codons, in-frame potential initiation codons; underlined AATAAA sequence, consensus polyadenylation signal.



Northern blot analysis using the full-length cDNA as a hybridization probe revealed mRNA species of approximately 7.5, 5.5, and 3.5 kb predominantly in the lung and to a lesser degree in the heart (Fig. 2A). RNA dot-blot analysis of over 20 different human tissues indicated widespread, but generally low levels, of receptor mRNA expression (data not shown). In situ analysis of mouse lung and heart tissues demonstrated specific expression of the CGRP(1) receptor mRNA in alveolar cells in the lung and cardiac myocytes in the heart (Fig. 2B).


Figure 2: Tissue expression of CGRP(1) receptor mRNA. A, Northern blot analysis of CGRP(1) mRNA expression. RNA size markers are indicated on the left. B, in situ gene amplification analysis of CGRP(1) mRNA expression. The adjacent sections of mouse lung (a, b, c, d, times 100) and heart (e, f, g, h, times 400) were used for these studies. a and e, use of the reverse transcriptase. b and f, omission of the reverse transcriptase. c and g, omission of amplification primers. d and h, hematoxylin and eosin staining.



To determine the binding and functional properties of the receptor, we used HEK 293 cells stably transfected with the cDNA subcloned within an expression vector. Membranes prepared from untransfected 293 cells had very little specific I-CGRP binding (data not shown). Membranes prepared from transfected 293 cells displayed high-affinity, low-density binding sites for I-CGRP. The apparent dissociation constant (K(d)) and maximum binding (B(max)) were 19 ± 3 pM and 86 ± 14 fmol/mg protein, respectively (Fig. 3A). In competition binding studies, the rank order potency for a series of related peptides to inhibit I-CGRP binding to these membranes was CGRP > CGRP-(8-37) > Cys(ACM2,7)CGRP > adrenomedullin (ADM) > salmon CT-(8-32) >>> salmon CT > human CT > vasoactive intestinal peptide > angiotensin II (Fig. 3B). The binding affinity of I-CGRP for the recombinant receptor as well as the pharmacological profile of the competing ligands were very similar to that observed for endogenous CGRP receptors present in membranes prepared from human neuroblastoma SK-N-MC cells (Fig. 3C).


Figure 3: Pharmacological characterization of the recombinant CGRP receptor stably expressed in 293 cells. A, representative saturation curve for I-CGRP binding to the membranes prepared from 293 cells expressing the recombinant CGRP receptor. , total binding; , nonspecific binding; and bullet, specific binding. Inset, corresponding Scatchard plot of the data. B, competition binding profile of CGRP () and its analogs CGRP-(8-37) (), Cys(ACM2,7)CGRP (circle), ADM (), salmon CT (), salmon CT-(8-32) (bullet), human CT (box), angiotensin II (), and vasoactive intestinal peptide (down triangle) for specific I-CGRP binding to the membranes. C, competition binding profile of CGRP and its analogs for specific I-CGRP binding to SK-N-MC cell membranes.



Previous studies have shown that CGRP mediates its responses by activation of adenylyl cyclase and the generation of cyclic AMP(4, 5) . Treatment of vector-transfected 293 cells with CGRP induced less than a 2-fold increase in the accumulation of cAMP (Fig. 4A). Addition of CGRP to 293 cells expressing the recombinant receptor resulted in an increased accumulation of cAMP that was concentration-dependent (Fig. 4B). The threshold, half-maximal, and maximal concentrations of CGRP required to stimulate cAMP accumulation in these cells were 0.1, 0.9, and 10 nM, respectively. The maximal stimulation in response to agonist was 60-fold over basal levels of cAMP. Again, these results were comparable to those achieved using SK-N-MC cells containing endogenous CGRP receptors(35) . Treatment of cDNA-transfected 293 cells with increasing concentrations of CGRP-(8-37), a selective CGRP receptor antagonist, shifted the CGRP concentration response curve for cAMP accumulation to the right in a parallel manner, indicating competitive inhibition with a calculated pA(2) value of 7.57 (Fig. 4C). Except at high concentrations (1 µM), the CGRP(2) receptor-selective agonist Cys(ACM2,7)CGRP failed to stimulate cAMP in both receptor-transfected cells (Fig. 4B) and SK-N-MC cells (data not shown). The effect of Cys(ACM2,7)CGRP on the recombinant CGRP receptor in inhibiting only I CGRP binding but not a functional cAMP response to CGRP is consistent with the properties of the native rat CGRP(1) receptor present in spleen membranes(36) . Thus, the receptor described in the present study is a CGRP(1) receptor.


Figure 4: Functional characterization of the recombinant CGRP receptor. A and B, concentration-dependent effects of CGRP (), ADM (), human CT (), and Cys(ACM2,7)CGRP (up triangle) on cAMP accumulation in CDN vector-transfected 293 cells (A) and CGRP receptor-transfected 293 cells (B). C, effect of CGRP-(8-37) on CGRP-mediated cAMP response in the absence or presence of 100 or 300 nM CGRP-(8-37). The antagonist effect was studied by performing CGRP concentration response curves in the absence () and presence of 100 () and 300 () nM CGRP-(8-37).



At high concentrations, ADM evoked a specific response (Fig. 4B), which was not surprising since this agonist has been reported to interact weakly with the CGRP receptor(37) . In contrast, human CT does not interact with the recombinant receptor, since this ligand stimulated a nearly identical activity in both CGRP receptor- and vector control-transfected cells (Fig. 4, A and B). Collectively, the pharmacological and functional results confirm that the receptor cDNA encodes a human CGRP(1) receptor that is functionally coupled to the activation of adenylyl cyclase.

Although originally identified as an orphan rat CT-like receptor (18) and, very recently, classified as an orphan human CT-like receptor (despite testing for interaction with CGRP in addition to other ligands (19) ), the results presented within this report clearly demonstrate that we have cloned a CGRP(1) receptor. As to the reason why previous investigators were unable to identify the reported CT-like receptor as the CGRP(1) receptor is only a matter of speculation. It is possible that the recombinant CGRP receptor can be functionally expressed only in certain cell types. In this study we used HEK 293 cells, whereas in other reports it appears that only COS and OK cells were used for receptor evaluation. We have recently cloned the porcine CGRP(1) receptor ortholog of the human receptor and found it to exhibit essentially identical pharmacological properties, which provides further supporting evidence that we have identified the CGRP(1) receptor. (^2)The availability of the CGRP(1) receptor should facilitate the study of the physiology and pathophysiology of CGRP as a neurotransmitter, neuromodulator, local hormone, and inflammatory mediator.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank(TM)/EMBL Data Bank with accession number(s) L76380[GenBank].

§
To whom correspondence may be addressed: Dept. of Molecular Genetics, SmithKline Beecham Pharmaceuticals, 709 Swedeland Rd., King of Prussia, PA 19406. Tel.: 610-270-7610; Fax: 610-270-7962.

To whom correspondence may be addressed: Dept. of Molecular Genetics, Human Genome Sciences, Inc., 9410 Key West Ave., Rockville, MD 20850. Tel.: 301-309-8504; Fax: 301-340-7159.

(^1)
The abbreviations used are: CGRP, calcitonin gene-related peptide; EST, expressed sequence tag; CT, calcitonin; bp, base pair(s); PCR, polymerase chain reaction; ADM, adrenomedullin.

(^2)
N. Aiyar, K. Rand, N. A. Elshourbagy, Z. Zeng, J. E. Adamou, D. J. Bergsma, and Y. Li, manuscript in preparation.


ACKNOWLEDGEMENTS

We thank the following for their support of the work: William Haseltine, Craig Rosen, Michael Antonaccio, Pat Dillon, Gou-Liang Yu, and Lily Xing at Human Genome Sciences, the sequencing group at The Institute for Genomic Research, Martin Rosenberg, Robert Ruffolo, Jr., Christine Debouck, Giora Feurstein, Jeff Stadel, George Livi, Ganesh Sathe, and Subinay Ganguly at SmithKline Beecham Pharmaceuticals.


REFERENCES

  1. Amara, S. G., Jonas, V, Rosenfeld, M. G., Ong, E. S., and Evans, R. M. (1982) Nature 298, 240-244 [Medline] [Order article via Infotrieve]
  2. Amara, S. G., Arriza, J. I., Leff, S. E., Swanson, L. W., Evans, R. M., and Rosenfeld, M. G. (1985) Science 229, 1094-1097 [Medline] [Order article via Infotrieve]
  3. Brain, S. D., Williams, T. J., Tippins, J. R., Morris, H. R., and MacIntyre, I. (1985) Nature 313, 54-56 [Medline] [Order article via Infotrieve]
  4. Sigrist, S., Franco-Cereceda, A., Muff, R., Henke, H., Lundberg, J. M., and Fisher, J. A. (1986) Endocrinology 119, 381-389 [Abstract]
  5. Grunditz, T., Ekman, R., Hakanson, R., Rerup, C., Sunder, F., and Uddman, R. (1986) Endocrinology 119, 2313-2324 [Abstract]
  6. Fargeas, M. J., Fioramonti, J., and Bueno, L. (1985) Peptides 6, 1167-1171 [Medline] [Order article via Infotrieve]
  7. Hermansen, K., and Ahren, B. (1990) Regul. Pept. 27, 149-157 [Medline] [Order article via Infotrieve]
  8. Molina, J. M., Cooper, G. J. S., Leighton, B., Oletsky, J. M. (1990) Diabetes 39, 260-265 [Abstract]
  9. Tannenbaum, G. S., and Goltzman, D. (1985) Endocrinology 116, 2685-2687 [Abstract]
  10. Muff, R, Born, W., and Fischer, J. A. (1995) Eur. J. Endocrinol. 133, 17-20 [Medline] [Order article via Infotrieve]
  11. Goodman, E. C., and Iversen, L. L. (1986) Life Sci. 38, 2169-2178 [CrossRef][Medline] [Order article via Infotrieve]
  12. Poyner, D. R. (1992) Pharmacol. Ther. 56, 23-51 [CrossRef][Medline] [Order article via Infotrieve]
  13. Kubota, M., Moseley, J. M., Butera, L., Dusting, G. J., Macdonald, P. S., and Martin, T. J. (1985) Biochem. Biophys. Res. Commun. 132, 88-94 [Medline] [Order article via Infotrieve]
  14. Dennis, T., Fournier, A., Guard, S., St. Pierre, S., and Quirion, R. (1991) Brain Res. 539, 59-66 [CrossRef][Medline] [Order article via Infotrieve]
  15. Adams, M. D., Kelley, J. M., Gocayne, J. D., Dubnick, M., Polymeropoulos, M. H., Xiao, H., Merril, C. R., Wu, A., Olde, B., Moreno, R. F., Kerlavage, A. R., McCombie, W. R., and Venter, J. C. (1991) Science 252, 1651-1656 [Medline] [Order article via Infotrieve]
  16. Adams, M. D., Dubnick, M., Kerlavage, A. R., Moreno, R., Kelley, J. M., Kelly, J. M., Utterback, T. R., Nagle, J. W., Fields, C., and Venter, J. C. (1992) Nature 355, 632-634 [CrossRef][Medline] [Order article via Infotrieve]
  17. Adams, M. D., Kerlavage, A. R., Floischmann, R. D., Fuldner, R. A., Buit, C. J., Lee, N. H., Kirkness, E. F., Weinstock, K. G., Gocayne, J. D., White, O., Sutton, G., Slake, J. A., Brandon, R. C., Chiu, M.-W., Clayton, R. A., Cline, R. T., Cofton, M. D., Earle-Hughes, J., Fine, L. D., FitzGerald, L. M., FitzHugh, W. M., Fritchman, J. L., Geoghegan, N. S. M., Giodek, A., Gnehm, C. L., Hanna, M. C., Hodblom, E., Hinkle, P. S., Jr., Kelley, J. M., Klimek, K. M., Kelley, J. C., Liu, L.-I., Marmaros, S. M., Merrick, J. M., Moreno-Palanques, R. F., McDonald, L. A., Nguyen, D. T., Pellegrino, S. M., Phillips, C. A., Ryder, S. E., Scott, J. L., Saudek, D. M., Shirley, R., Small, K. V., Spriggs, T. A., Utterback, T. R., Weidman, J. F., Li, Y., Barthlow, R., Bednarik, D. P., Coo, L., Copeda, M. A., Coleman, T. A., Collins, E.-J., Dimke, D., Fang, P., Ferris, A., Fischer, C., Hastings, G. A., He, W.-W., Hu, J.-S., Huddleston, K. A., Greene, J. M., Gruber, J., Hudson, P., Kim, A., Kozak, D. L., Kunsch, C., Ji, H., Li, H., Moissner, P. S., Olson, H., Raymond, L., Wei, Y.-F., Wing, J., Xu, C., Yu, Q.-L., Ruben, S. M., Dillon, P. J., Fannon, M. R., Rosen, C. A., Haseltine, W. A., Fields, C., Fraser, C. M., and Venter, J. C. (1995) Nature 377, (suppl.) 3-174 [Medline] [Order article via Infotrieve]
  18. Chang, C. P., Pearse, R. V., II, O'Connell, S., and Rosenfeld, M. G. (1993) Neuron 11, 1187-1195 [Medline] [Order article via Infotrieve]
  19. Fluhmann, B., Muff, R., Hunziker, W., Fischer, J. A., and Born, W. (1995) Biochem. Biophys. Res. Commun. 206, 341-347 [CrossRef][Medline] [Order article via Infotrieve]
  20. Jelinek, L. J., Lok, S., Rosenberg, G. B., Smith, R. A., Grant, F. J., Biggs, S., Bensch, P. A., Kuijper, J. L., Sheppard, P. O., Sprecher, C. A., O'Hara, P. J., Foster, D., Walker, K. M., Chen, L. H. J., McKernan, P. A., and Kindsvogel, W. (1993) Science 259, 1614-1616 [Medline] [Order article via Infotrieve]
  21. Kozak, M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2662-2666 [Abstract]
  22. Aiyar, N., Baker, E., Wu, H.-L., Nambi, P., Edwards, R. M., Trill, J. J., Ellis, C., and Bergsma, D. J. (1994) Mol. Cell. Biol. 131, 75-86
  23. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  24. Nuovo, J. G. (1992) PCR in Situ Hybridization: Protocols and Applications , Raven Press, New York
  25. Aiyar, N., Nambi, P., Griffin, E., Bhatnager, P., and Feurstein, G. (1991) Endocrinology 129, 965-969 [Abstract]
  26. Lin, H. Y., Harris, T. L., Flannery, M. S., Aruffo, A., Kaji, E. H., Gorn, A., Kolakowski, L. F. Lodish, H. F., and Goldring, S. R. (1991) Science 254, 1022-1024 [Medline] [Order article via Infotrieve]
  27. Hirata, Y., Takagi, Y., Takata, S., Fukuda, Y., Yoshimi, H., and Fujita, T. (1988) Biochem. Biophys. Res. Commun. 151, 1113-1121 [Medline] [Order article via Infotrieve]
  28. Nawa, H., Kotani, H., and Nakanishi, S., (1984) Nature 312, 729-734 [Medline] [Order article via Infotrieve]
  29. Kozak, M. (1987) J. Mol. Biol. 196, 947-950 [Medline] [Order article via Infotrieve]
  30. Dohlman, H. G., Thorner, J., Caron, M. G., and Lefkowitz, R. J. (1991) Annu. Rev. Biochem. 60, 653-688 [CrossRef][Medline] [Order article via Infotrieve]
  31. Jackson, T. (1991) Pharmacol. Ther. 50, 425-442 [CrossRef][Medline] [Order article via Infotrieve]
  32. Ishihara, T., Nakamura, S., Kaziro, Y., Takahashi, T., Takahashi, T., and Nagata, S. (1991) EMBO J. 10, 1635-1641 [Abstract]
  33. Juppner, H., Abou-Samra, A. B., Freeman, M., Kong, X. F., Schipani, E., Richards, J., Kolakowski, L. F., Hock, J., Potts, J. T., Kronenberg, H. M., and Segre, G. V. (1991) Science 254, 1024-1026 [Medline] [Order article via Infotrieve]
  34. Thorens, B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8641-8645 [Abstract]
  35. van Valen, F., Piechot, G., and Jurgens, H. (1990) Neurosci. Lett. 119, 195-198 [CrossRef][Medline] [Order article via Infotrieve]
  36. Stangl, D., Muff, R., Schmolck, C., and Fischer, J. A. (1993) Endocrinology 132, 744-750 [Abstract]
  37. Kitamura, K., Kangawa, K., Kojima, M., Ichiki, Y., Matsuo, H., and Ito, T. (1994) FEBS Lett. 338, 306-310 [CrossRef][Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.